Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
The role of innate immunity in melanoma
FY 2020-21
Summary
Cutaneous melanoma is the most lethal form of skin cancer, and its incidence is increasing. In 2020, approximately 8,000 Canadians will have been diagnosed with cutaneous melanoma and 1,300 will have died from it. The current mainstay of treatment for advanced disease, immune checkpoint inhibitors (ICIs), have revolutionized patient outcomes. ICIs work by harnessing the patient's own immune system to recognize and kill tumour cells. However, adverse events related to this immune activation, including colitis, pneumonitis, and dermatitis, as well as resistance can limit use of ICIs. Group 2 innate lymphoid cells (ILC2s) are newly identified cells in humans with roles in cancer immunity. However, their specific pro- or anti-tumour effects in patients with melanoma, and their role in response to ICIs are unknown. This is the first-in-human study to determine the effects of ICIs on ILC2s and the role of ILC2s in response to ICIs and development of adverse events. This study will also demonstrate that the ILC2 immune response and ILC populations can be monitored using peripheral blood mononuclear cells isolated from patients with cancer. To assess the ILC2 response to ICIs, multi-parameter flow cytometry will be used to determine the levels of ILC2s in the blood of melanoma patients on ICIs at defined time intervals. Following extraction from the blood using cell sorting and ex vivo expansion, the functional properties of the ILC2s will be assessed. Statistical analyses will be performed to identify correlations between the presence of ILC2s and response rates and toxicities to ICIs. Ultimately, this innovative research will provide evidence for novel melanoma therapies that may offer greater efficacy and overcome the concerns associated with current treatments.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
449456
Name
Henderson Berg Meagan-Helen
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The role of innate immunity in melanoma
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Immune Adverse Events; Immune Checkpoint Inhibitors; Immunotherapy; Innate Lymphoid Cells; Melanoma
Abstract
Cutaneous melanoma is the most lethal form of skin cancer, and its incidence is increasing. In 2020, approximately 8,000 Canadians will have been diagnosed with cutaneous melanoma and 1,300 will have died from it. The current mainstay of treatment for advanced disease, immune checkpoint inhibitors (ICIs), have revolutionized patient outcomes. ICIs work by harnessing the patient's own immune system to recognize and kill tumour cells. However, adverse events related to this immune activation, including colitis, pneumonitis, and dermatitis, as well as resistance can limit use of ICIs. Group 2 innate lymphoid cells (ILC2s) are newly identified cells in humans with roles in cancer immunity. However, their specific pro- or anti-tumour effects in patients with melanoma, and their role in response to ICIs are unknown. This is the first-in-human study to determine the effects of ICIs on ILC2s and the role of ILC2s in response to ICIs and development of adverse events. This study will also demonstrate that the ILC2 immune response and ILC populations can be monitored using peripheral blood mononuclear cells isolated from patients with cancer. To assess the ILC2 response to ICIs, multi-parameter flow cytometry will be used to determine the levels of ILC2s in the blood of melanoma patients on ICIs at defined time intervals. Following extraction from the blood using cell sorting and ex vivo expansion, the functional properties of the ILC2s will be assessed. Statistical analyses will be performed to identify correlations between the presence of ILC2s and response rates and toxicities to ICIs. Ultimately, this innovative research will provide evidence for novel melanoma therapies that may offer greater efficacy and overcome the concerns associated with current treatments.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Henderson Berg, Meagan-Helen
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~